Pharmac decision disappoints

We're bitterly disappointed that Pharmac has decided not to fund bevacizumab for the treatment of recurrent or relapsed high-grade glioma (including glioblastoma). While not a silver bullet, bevacizumab can provide immediate symptom relief and extend the time before a patient's tumour progresses, meaning more quality time spent with loved ones. In the lead up to Christmas, this is all our patients are asking for.

Read our full media release in response to Pharmac’s decision.